Serina Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 1.94 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 49.28M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson’s disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson’s and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it ...